A Study of PBFT02 in Patients With Frontotemporal Dementia and Progranulin Mutations (FTD-GRN)
Status:
Recruiting
Trial end date:
2027-08-01
Target enrollment:
Participant gender:
Summary
PBFT02 is a gene therapy for frontotemporal dementia intended to deliver a functional copy of
the GRN gene to the brain. This study will assess the safety, tolerability and efficacy of
this treatment in patients with frontotemporal dementia and mutations in the progranulin gene
(FTD-GRN).